Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2023
• Auteurs : Sébastien BourdinPhilippe Jean-PierreDavid Perrain
• Organismes : Métis Lab EM Normandie Centre d'Économie et de Management de l'Océan Indien Institut d'Administration des Entreprises - La Réunion Centre d'Économie et de Management de l'Océan Indien Institut d'Administration des Entreprises - La Réunion
• Publié dans Eastern Journal of European Studies le 02/11/2020

---

Résumé : This article examines the issue of innovation in the tourism sector, emphasising its crucial role in the transformation of the tourist offer within European regions. Faced with territorial disparities in terms of tourism innovations, we examine the impact of Regional Innovation and Smart Specialization Strategies (RIS3) on the deployment of tourism innovation. By analysing the 2014-2020 program through a three-step action research study, we identify a positive correlation between RIS3 initiatives and innovation in the tourism industry. However, RIS3 seem to be a necessary but not sufficient condition to stimulate innovation.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2023
• Auteurs : Tae Won KimPhilippe BedardPatricia LorussoMichael GordonJohanna BendellDo-Youn OhMyung-Ju AhnElena GarraldaSandra D’angeloJayesh DesaiF. Stephen HodiZev WainbergJean-Pierre DelordPhillippe CassierAndrés CervantesMarta Gil-MartinBenjamin WuNamrata PatilYanling JinTien HoangDiana MendusXiaohui WenRaymond MengByoung Chul Cho
• Organismes : Centre de Recherches en Cancérologie de Toulouse Oncopole Claudius Regaud Institut Universitaire du Cancer de Toulouse - Oncopole
• Publié dans JAMA oncology le 27/10/2020

---

Résumé : Importance Inhibition of the T-cell immunoreceptor with Ig and ITIM domains (TIGIT)/poliovirus receptor pathway may amplify the antitumor immune response of atezolizumab in programmed death ligand 1–selected tumors. Objective To evaluate the safety and antitumor activity of the anti-TIGIT antibody tiragolumab and its combination with atezolizumab in patients with advanced solid tumors. Design, Setting, and Participants The GO30103 open-label, first-in-human phase 1a/1b dose-escalation and dose-expansion nonrandomized controlled trial was conducted at 13 sites in 6 countries (Australia, Canada, France, Korea, Spain, and the US). The start dates were May 23, 2016, for phase 1a and October 11, 2016, for phase 1b. Patients were aged 18 years or older with measurable disease at baseline. The clinical cutoff date was October 1, 2021. Data analysis was performed on January 24, 2022. Interventions Patients received fixed-dose intravenous tiragolumab on day 1 of each 21-day cycle (2 mg escalating to 1200 mg) in phase 1a, plus fixed-dose intravenous atezolizumab (1200 mg every 3 weeks) in phase 1b. Patients were treated until disease progression, loss of clinical benefit, or development of unacceptable toxicity. Main Outcomes and Measures The primary end points included the safety, tolerability, and recommended phase 2 dose (RP2D) of tiragolumab or combination tiragolumab plus atezolizumab. The secondary end point included the investigator-assessed objective response rate (ORR). Counts and percentages are used for categorical variables, and medians and ranges are used for continuous variables. Results Among the phase 1a (n = 24) and 1b (n = 49) dose-escalation cohorts, the median age was 60 (range, 40-77) and 54 (range, 25-81) years, respectively. More than half of patients were women (14 of 24 [58%] and 25 of 49 [51%]), and more than a third (10 [42%] and 18 [37%]) had received 4 or more prior cancer therapies. No dose-limiting toxicities occurred, and the maximum tolerated dose of tiragolumab was not reached (NR). The most frequent treatment-related adverse events (AEs) were fatigue (5 of 24 [21%]) in phase 1a and pruritus (5 of 49 [10%]) in phase 1b; the majority of AEs were grade 1 or 2. Immune-mediated AEs occurred in 4 of 24 (17%) and 29 of 49 (59%) patients during phases 1a and 1b, respectively (primarily grade 1 or 2). The RP2D of tiragolumab was 600 mg intravenously every 3 weeks, which was tested in phase 1b dose expansion. The confirmed ORR was 0% during phase 1a, with evidence of antitumor activity in 6% of patients (n = 3) during phase 1b. The safety profile of combination tiragolumab plus atezolizumab in phase 1b was similar in the dose-escalation and dose-expansion cohorts. The confirmed ORR was 46% (6 of 13) in the non–small cell lung cancer (NSCLC) cohort (median duration of response [DOR], NR) and 28% (5 of 18) in the esophageal cancer (EC) cohort (median DOR, 15.2 [95% CI, 7.0 to NR] months). Conclusions and Relevance In this nonrandomized controlled trial, tiragolumab was well tolerated with or without atezolizumab; no new safety signals were observed. Preliminary antitumor activity was demonstrated for the combination regimen in patients with cancer immunotherapy–naive metastatic NSCLC or EC. Trial Registration ClinicalTrials.gov Identifier: NCT02794571

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2023
• Auteurs : Tae Won KimPhilippe BedardPatricia LorussoMichael GordonJohanna BendellDo-Youn OhMyung-Ju AhnElena GarraldaSandra D’angeloJayesh DesaiF. Stephen HodiZev WainbergJean-Pierre DelordPhillippe CassierAndrés CervantesMarta Gil-MartinBenjamin WuNamrata PatilYanling JinTien HoangDiana MendusXiaohui WenRaymond MengByoung Chul Cho
• Organismes : Centre de Recherches en Cancérologie de Toulouse Oncopole Claudius Regaud Institut Universitaire du Cancer de Toulouse - Oncopole
• Publié dans JAMA oncology le 27/10/2020

---

Résumé : Importance Inhibition of the T-cell immunoreceptor with Ig and ITIM domains (TIGIT)/poliovirus receptor pathway may amplify the antitumor immune response of atezolizumab in programmed death ligand 1–selected tumors. Objective To evaluate the safety and antitumor activity of the anti-TIGIT antibody tiragolumab and its combination with atezolizumab in patients with advanced solid tumors. Design, Setting, and Participants The GO30103 open-label, first-in-human phase 1a/1b dose-escalation and dose-expansion nonrandomized controlled trial was conducted at 13 sites in 6 countries (Australia, Canada, France, Korea, Spain, and the US). The start dates were May 23, 2016, for phase 1a and October 11, 2016, for phase 1b. Patients were aged 18 years or older with measurable disease at baseline. The clinical cutoff date was October 1, 2021. Data analysis was performed on January 24, 2022. Interventions Patients received fixed-dose intravenous tiragolumab on day 1 of each 21-day cycle (2 mg escalating to 1200 mg) in phase 1a, plus fixed-dose intravenous atezolizumab (1200 mg every 3 weeks) in phase 1b. Patients were treated until disease progression, loss of clinical benefit, or development of unacceptable toxicity. Main Outcomes and Measures The primary end points included the safety, tolerability, and recommended phase 2 dose (RP2D) of tiragolumab or combination tiragolumab plus atezolizumab. The secondary end point included the investigator-assessed objective response rate (ORR). Counts and percentages are used for categorical variables, and medians and ranges are used for continuous variables. Results Among the phase 1a (n = 24) and 1b (n = 49) dose-escalation cohorts, the median age was 60 (range, 40-77) and 54 (range, 25-81) years, respectively. More than half of patients were women (14 of 24 [58%] and 25 of 49 [51%]), and more than a third (10 [42%] and 18 [37%]) had received 4 or more prior cancer therapies. No dose-limiting toxicities occurred, and the maximum tolerated dose of tiragolumab was not reached (NR). The most frequent treatment-related adverse events (AEs) were fatigue (5 of 24 [21%]) in phase 1a and pruritus (5 of 49 [10%]) in phase 1b; the majority of AEs were grade 1 or 2. Immune-mediated AEs occurred in 4 of 24 (17%) and 29 of 49 (59%) patients during phases 1a and 1b, respectively (primarily grade 1 or 2). The RP2D of tiragolumab was 600 mg intravenously every 3 weeks, which was tested in phase 1b dose expansion. The confirmed ORR was 0% during phase 1a, with evidence of antitumor activity in 6% of patients (n = 3) during phase 1b. The safety profile of combination tiragolumab plus atezolizumab in phase 1b was similar in the dose-escalation and dose-expansion cohorts. The confirmed ORR was 46% (6 of 13) in the non–small cell lung cancer (NSCLC) cohort (median duration of response [DOR], NR) and 28% (5 of 18) in the esophageal cancer (EC) cohort (median DOR, 15.2 [95% CI, 7.0 to NR] months). Conclusions and Relevance In this nonrandomized controlled trial, tiragolumab was well tolerated with or without atezolizumab; no new safety signals were observed. Preliminary antitumor activity was demonstrated for the combination regimen in patients with cancer immunotherapy–naive metastatic NSCLC or EC. Trial Registration ClinicalTrials.gov Identifier: NCT02794571

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2023
• Auteurs : Mélanie CognéArthur DelayrePauline CoignardJean-Luc Le GuietPierre-Alain JosephIsabelle BonanEric SoritaClaire Le GallPhilippe Azouvi
• Organismes : Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Oncostat Hôpital Raymond Poincaré [AP-HP] Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de KERPAPE [Ploemeur] Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de KERPAPE [Ploemeur] Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de KERPAPE [Ploemeur] Handicap et système nerveux :Action, communication, interaction: rétablissement de la fonction et de la participation [Bordeaux] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Neuroimagerie: méthodes et applications Bordeaux population health Université de Bretagne Occidentale - UFR Médecine et Sciences de la Santé - Brest Centre de recherche en épidémiologie et santé des populations
• Publié dans Annals of Physical and Rehabilitation Medicine le 02/11/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2023
• Auteurs : Francesco MorandiniKevin PerezLoic BrotSidy Mohammed SeckLaurence TibèreJean-Pierre GrillEnguerran MaciaPhilippe Seksik
• Organismes : University of Rochester [USA] Université de Lausanne = University of Lausanne Centre de Recherche Saint-Antoine CHU Saint-Antoine [AP-HP] Unité Mixte Internationale "Environnement Santé Sociétés" Centre d'Etude et de Recherche Travail Organisation Pouvoir Centre de Recherche Saint-Antoine Unité Mixte Internationale "Environnement Santé Sociétés" Anthropologie bio-culturelle, Droit, Ethique et Santé CHU Saint-Antoine [AP-HP] Centre de Recherche Saint-Antoine FHU Paris Center for Microbiome Medicine
• Publié dans iScience le 17/01/2019

---

Résumé : Alterations of the microbiome are linked to increasingly common diseases such as obesity, allergy, and inflammatory bowel disease. Post-industrial lifestyles are thought to contribute to the gut microbiome alterations that cause or aggravate these diseases. Comparing communities across the industrialization spectrum can reveal associations between gut microbiome alterations and lifestyle and health, and help pinpoint which specific aspect of the post-industrial lifestyle is linked to microbiome alterations. Here, we compare the gut microbiomes of 60 mother and infant pairs from rural and urban areas of Senegal over two time points. We find that urban mothers, who were more frequently overweight, had different gut microbiome compositions than rural mothers, showing an expansion of Lachnospiraceae and Enterobacter. Urban infants, on the other hand, showed a delayed gut microbiome maturation and a higher susceptibility to infectious diseases. Thus, we identify new microbiome features associated with industrialization, whose association with disease may be further investigated.

---

Fichiers liés : Microbiote Senegal - Macia.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2023
• Auteurs : Geoffroy RambaudVicky MaiCamille MotreffOlivier SanchezPierre-Marie RoyYannick AuffretRaphael Le MaoFrédéric GagnadouxNicolas PaleironJeannot SchmidtJean PastreMichel NonentCécile TromeurPierre-Yves SalaunPatrick MismettiPhilippe GirardKarine LacutCatherine LemariéGuy MeyerChristophe LeroyerGrégoire Le GalLaurent BertolettiFrancis Couturaud
• Organismes : Hôpital Morvan - CHRU de Brest Innovations thérapeutiques en hémostase = Innovative Therapies in Haemostasis Santé Ingénierie Biologie Saint-Etienne Centre d'Investigation Clinique - Epidémiologie Clinique [CHU Saint-Etienne] Santé Ingénierie Biologie Saint-Etienne
• Publié dans Thrombosis Research le 22/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2023
• Auteurs : Antoine FayandMargaux CescatoLaurent Le CorreAlexandre TerréMargaux WacheuxYixiang Yj. ZhuArmelle MeletThomas Rj. MoreauBahram BodaghiFabrice BonnetDidier BronnimannLaurence CuissetRaquel FariaGilles GrateauPascal PilletCatharina Mulders-MandersBenedicte NevenPierre QuartierOlivier RicherLéa SaveyMarie-Elise TruchetetBénédicte PyGuilaine BoursierJean Philippe HerbeuvalSophie Georgin-LavialleMathieu P Rodero
• Organismes : CHU Tenon [AP-HP] Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques CHU Tenon [AP-HP] Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques Immunologie Translationnelle - Translational Immunology lab Immunologie - Immunopathologie - Immunothérapie [CHU Pitié Salpêtrière] Bordeaux population health Global Health in the Global South Centre Hospitalier Universitaire de Bordeaux Hôpital Cochin [AP-HP] Universidade do Porto = University of Porto Groupe de recherche clinique Amylose AA Sorbonne Université Centre Hospitalier Universitaire de Bordeaux Radboud University Medical Center [Nijmegen] Hôpital Necker - Enfants Malades [AP-HP] Université Paris Cité Immunogenetics of pediatric autoimmune diseases Imagine - Institut des maladies génétiques (IHU) Centre Hospitalier Universitaire de Bordeaux Groupe de recherche clinique Amylose AA Sorbonne Université Hôpital Pellegrin Centre International de Recherche en Infectiologie Inflammasome NLRP3 et réponse immunitaire au sepsis - NLRP3 inflammasome and immune response to sepsis [CIRI] CHU Montpellier = Montpellier University Hospital Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques CHU Tenon [AP-HP] Sorbonne Université Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques
• Publié dans Journal of Allergy and Clinical Immunology le 31/10/2020

---

Résumé : Background: Cryopyrin-associated periodic syndrome (CAPS) is associated with NLRP3 pathogenic variants, mostly located in the NACHT domain. Cold induced urticarial rash is one of the main clinical features. We however identified a series of 14 patients with pathogenic variants of the Y861 residue (p.Tyr861) of the LRR domain of NLRP3 and minimal prevalence of cold-induced urticarial rash. Objective: We aimed to address a possible genotype / phenotype correlation for CAPS patients and to investigate at the cellular levels the impact of the Y861C substitution (p.Tyr861Cys) on NLRP3 activation. Methods: Clinical features of 14 CAPS patients with heterozygous substitution at position 861 in the LRR domain of NLRP3 were compared to clinical features of 48 CAPS patients with pathogenic variants outside the LRR domain of NLRP3. IL-1β secretion by PBMCs and purified monocytes from patients and healthy donors was evaluated following LPS and MSU stimulation. Results: Patients with substitution at position 861 of NLRP3 demonstrated a higher prevalence of sensorineural hearing loss while being less prone to skin urticarial. In contrast to classical CAPS patients, cells from patients with a pathogenic variant at position 861 required an activation signal to secrete IL-1β but produced more IL-1β during the early and late phase of secretion than cells from healthy donors. Conclusion: Pathogenic variants of Y861 of NLRP3 drive a boost-dependent over secretion of IL-1β associated with an atypical CAPS phenotype.

---

Fichiers liés : combine-Fayand-et-al.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2023
• Auteurs : Pierre-Louis DeclercqIsabelle FournelMatthieu DemeyereAnissa BerraiesEléa KsiazekMartine NyungaCédric DaubinAlexandre AmpereBertrand SauneufJulio BadieAgathe DelboveSaad NseirElise Artaud-MacariVanessa BironneauMichel RamakersJulien MaizelArnaud-Felix MiailheBéatrice LacombeNicolas DelbergheWalid OulehriHugues GeorgesXavier TchenioCaroline ClarotElise RedureauGaël BourdinLaura FedericiMélanie AddaDavid SchnellMehdi BoustaCharlotte Salmon GandonnièreThierry VanderlindenGaëtan PlantefeveDavid DelacourCyrille DelpierreGurvan Le BouarNicholas SedillotGaëtan BeduneauAntoine RivièreNicolas Meunier-BeillardStéphanie GélinotteJean-Philippe RigaudMarie LabruyèreMarjolaine GeorgesChristine BinquetJean-Pierre QuenotCrics-Triggersep GroupMélody de JesusSébastien NormantJean-Nicolas DacherThomas StoupChristophe VinsonneauAnne DewatinePierre CuchetDelphine RotsJulien CalusGabriel Le MoelPierre KalfonGaëtan BadreJean-François RoyDamien RouxJean-Damien RicardMarie MarcqThomas GeorgesCaroline PoupletLaurie LagacheNicolas MassonMatthieu DevosRaphaël FavorySébastien PréauAlexandre GaudetPierre BoujuLidia NichitaPascal MaignanLaurence LabourotFrancesco MolinariLaurence ThirardCharlotte LarratFernando BerdaguerMeltem Karakaya AkgunYannick FedunThiphaine GuyMarie GousseffDéborah BoyerTristan BonnevieElsa DemarestSami HraiechAude SylvestreCéline SanzAnne Veinstein
• Organismes : Centre hospitalier de Dieppe Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques Service de Radiologie [CHU Rouen] Centre hospitalier de Dieppe Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques Centre Hospitalier de Roubaix Service d'Anesthésie - Réanimation Chirurgicale [CHU Caen] Centre Hospitalier de Béthune CH Centre Hospitalier Public du Cotentin Hôpital Nord Franche-Comté [Hôpital de Trévenans] Centre hospitalier Bretagne Atlantique (Morbihan) Centre Hospitalier Régional Universitaire [CHU Lille] Service de pneumologie, oncologie thoracique et soins intensifs respiratoires [Rouen] Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Service de Soins Intensifs [CHU Caen] CHU Amiens-Picardie Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Groupe Hospitalier Bretagne Sud Service de pneumologie, oncologie thoracique et soins intensifs respiratoires [Rouen] Centre Hospitalier Universitaire [Strasbourg] Centre Hospitalier de Tourcoing Centre Hospitalier Fleyriat [Bourg en Bresse] Centre Hospitalier d'Abbeville Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon Centre hospitalier Saint Joseph - Saint Luc [Lyon] Hôpital Louis Mourier - AP-HP [Colombes] Assistance Publique - Hôpitaux de Marseille Centre Hospitalier d'Angoulême Groupe Hospitalier du Havre Centre Hospitalier Régional Universitaire de Tours Experience ; Technology & Human Interactions ; Care & Society : Centre hospitalier Victor Dupouy [Centre hospitalier d'Argenteuil] Clinique des cèdres - Ramsay Santé Equipe EQUITY (CERPOP) Centre Hospitalier Eure-Seine - Hôpital d'Evreux - Vernon (Evreux) Centre Hospitalier Fleyriat [Bourg en Bresse] UNIROUEN - UFR Santé CHU Rouen Centre Hospitalier d'Abbeville Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques Centre hospitalier de Dieppe Centre hospitalier de Dieppe CHU Dijon Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques CHU Dijon Centre des Sciences du Goût et de l'Alimentation [Dijon] CHU Dijon Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques CHU Dijon Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques Réseau CRICS-TRIGGERSEP [Clinical Research in Intensive Care and Sepsis - TRIal Group for Global Evaluation and Research in SEPsis – Labellisé F-CRIN (French Clinical Research Infrastructure Network)]
• Publié dans Intensive Care Medicine le 27/10/2020

---

Résumé : No abstract available

---

Fichiers liés : s00134-023-07217-2.pdf

---

Source

---

• Type de publi. : Autre publication
• Date de publi. : 01/11/2023
• Auteurs : Olivier GuptaMarie-Christine BardetPierre-Franck ChevetMarie-Pierre CometsDaniel DelalandeAlain DelmestreJean-Luc GodetOlivier GuptaAndré-Claude LacosteJean-Christophe NielPhilippe Saint Raymond
• Organismes : Autorité de sureté nucléaire [France] = Nuclear Safety Authority [France] Autorité de sureté nucléaire [France] = Nuclear Safety Authority [France] Autorité de sureté nucléaire [France] = Nuclear Safety Authority [France] Autorité de sureté nucléaire [France] = Nuclear Safety Authority [France] Autorité de sureté nucléaire [France] = Nuclear Safety Authority [France] Autorité de sureté nucléaire [France] = Nuclear Safety Authority [France] Autorité de sureté nucléaire [France] = Nuclear Safety Authority [France] Autorité de sureté nucléaire [France] = Nuclear Safety Authority [France] Autorité de sureté nucléaire [France] = Nuclear Safety Authority [France] Institut de Radioprotection et de Sûreté Nucléaire Autorité de sureté nucléaire [France] = Nuclear Safety Authority [France]

---

Résumé : Ce premier numéro des Cahiers Histoire de l’ASN est consacré au thème des « accidents nucléaires ». Si certains accidents nucléaires sont connus, au point d’ailleurs que leur nom propre est entré dans le langage courant, d’autres oscillent entre mémoire et oubli. C’est le cas pour deux accidents décrits dans ce numéro, ceux de Saint-Laurent-des-Eaux. Or, nous avons un devoir de construire une mémoire collective en capacité de servir pour demain. Trois idées clés nous semblent devoir être retenues à ce stade. D’abord, dans une société qui se veut sans risque, il est nécessaire de rappeler que le risque zéro n’existe pas et le nucléaire n’échappe pas à cette règle universelle. Comme le rappelle André-Claude Lacoste, président de l’ASN de 2006 à 2012, « personne ne peut garantir qu’il n’y aura jamais un accident grave en France. Il convient de faire deux choses : essayer de réduire la probabilité que cela arrive, ainsi que les conséquences, si cela arrive. C’est toute la philosophie de la sûreté nucléaire ». Ensuite, vis-à-vis des accidents du passé, il est nécessaire d’aller au-delà du caractère unique de ceux-ci pour en explorer les causes profondes et en tirer les enseignements qui permettront d’anticiper le potentiel accident, de le gérer au mieux, ainsi que la phase postaccidentelle. Nombre d’évolutions en matière organisationnelle ou de doctrine de sûreté nucléaire et de radioprotection proviennent de ce travail de retour d’expérience. Nous avons choisi de décrire ce travail au travers de cinq événements marquants, qui ont chacun généré des avancées majeures en matière de sûreté nucléaire et de radioprotection. Enfin, une des conséquences des accidents majeurs est bien l’émergence d’une conscience internationale des risques liés au nucléaire. Le message selon lequel la sûreté nucléaire est un bien commun et ne doit pas faire l’objet d’une compétition ou bien encore de manipulations géostratégiques, demeure, au regard des événements récents, plus que jamais d’actualité.

---

Fichiers liés : Les cahiers Histoire de l'ASN n°1 Accidents nucléaires et évolutions de la sûreté et de la radioprotection.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2023
• Auteurs : Emeline CuvilliezJean Claude DesportStéphane MeyerGéraldine LautretteCarole VillemonteixSandra GuérinCorentin VarrierAurélie LavaudPhilippe FayemendyPierre JésusJean Louis Fraysse
• Organismes : Nutrition Resources Center CERENUT, Isle EHPAD - Résidence du Parc - 87350 PANAZOL Service de Neurologie [CHU Limoges] Nutrition Resources Center CERENUT, Isle Nutrition Resources Center CERENUT, Isle Nutrition Resources Center CERENUT, Isle Nutrition Resources Center CERENUT, Isle Nutrition Resources Center CERENUT, Isle Epidémiologie des Maladies Chroniques en zone tropicale Nutrition Unit, CHU Limoges Nutrition Resources Center CERENUT, Isle Epidémiologie des Maladies Chroniques en zone tropicale Nutrition Unit, CHU Limoges
• Publié dans Nutrition Clinique et Métabolisme le 23/06/2025

---

Source